Search

Your search keyword '"Jentzsch M"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Jentzsch M" Remove constraint Author: "Jentzsch M"
145 results on '"Jentzsch M"'

Search Results

2. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

5. Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cells

7. P509: CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION

8. P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS

9. S287: FACTORS INFLUENCING AUTOLOGOUS LYMPHOCYTE COLLECTIONS FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS – THE ROLE OF T-CELL SENESCENCE

16. STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BENDAMUSTINE, PREDNISONE AND BORTEZOMIB INDUCTION IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT.

21. Stem Cell Mobilization and Autologous Stem Cell Transplantation after Pretreatment consisting of Bendamustine, Prednisone and Bortezomib (BPV) in 35 Patients with newly diagnosed/untreated Multiple Myeloma

22. Successful Treatment of Patients With Newly Diagnosed/Untreated Light Chain Multiple Myeloma With a Combination of Bendamustine; Prednisone and Bortezomib (BPV)

31. Thiamine-Responsive Megaloblastic Anemia (TRMA) Syndrome mimicking myelodysplastic neoplasm (MDS).

32. Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.

33. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma.

34. MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.

35. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.

36. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.

37. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.

38. Platelet transcription factors license the pro-inflammatory cytokine response of human monocytes.

39. Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma.

40. Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.

41. Optimising postoperative care: Same-day discharge after transurethral resection of the prostate.

42. Detection of Bartonella schoenbuchensis (sub)species DNA in different louse fly species in Saxony, Germany: The proof of multiple PCR analysis necessity in case of ruminant-associated bartonellae determination.

43. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.

44. Analysis of the peel structure of different Citrus spp. via light microscopy, SEM and μCT with manual and automatic segmentation.

46. Red blood cell distribution width (RDW) is associated with unfavorable functional outcome after transfemoral transcatheter aortic valve implantation.

47. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.

48. Management of Patients Undergoing CAR-T Cell Therapy in Germany.

49. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.

50. Design principles for cyclin K molecular glue degraders.

Catalog

Books, media, physical & digital resources